Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal

Fineline Cube Apr 15, 2026
Company Deals

Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate

Fineline Cube Apr 15, 2026
Company Deals

WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Fineline Cube Apr 14, 2026
Company Deals

Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization

Fineline Cube Apr 14, 2026
Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Policy / Regulatory

FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing

Fineline Cube Apr 15, 2026
Company Drug

Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication

Fineline Cube Apr 15, 2026
Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Fineline Cube Apr 15, 2026
Company Policy / Regulatory

Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations

Fineline Cube Apr 28, 2024

Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation...

Company Deals

Neusoft Medical Systems Partners with West China Hospital to Boost Indigenous Medical Tech Innovation

Fineline Cube Apr 28, 2024

China-based Neusoft Medical Systems Co., Ltd has entered into a strategic partnership with West China...

Company Deals

AbelZeta Pharma’s CAR-T Therapy C-CAR031 Receives Implicit Approval for Clinical Study in China

Fineline Cube Apr 28, 2024

Sino-US biotechnology company AbelZeta Pharma Inc., operating in Rockville, Maryland, and Shanghai, China, has received...

Company

Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups

Fineline Cube Apr 28, 2024

Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation...

Company

AstraZeneca Reports 19% YOY Revenue Growth in Q1 2024, Driven by Oncology and R&I

Fineline Cube Apr 26, 2024

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released an impressive set of financial results...

Company Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty Receives CE Mark for European Expansion

Fineline Cube Apr 26, 2024

China-based MicroPort Scientific Corp (HKG: 0853), a leading medical device company, announced that its spin-off,...

Company Deals

Allgens Medical Technology to Acquire German Dental Implant Maker HumanTech Dental for EUR 3.25 Million

Fineline Cube Apr 26, 2024

Beijing-based Allgens Medical Technology Co., Ltd (SHA: 688613), specializing in regenerative medicine materials and implantable...

Company Drug

Wuhan Bio-Raid Biotechnology Secures NMPA Approval for First-in-Class CD99-Targeted CAR-T Therapy

Fineline Cube Apr 26, 2024

Wuhan Bio-Raid Biotechnology Co., Ltd, a leading developer of chimeric antigen receptor (CAR)-T cell therapies...

Company

Clover Biopharmaceuticals Reports First Commercial Sales and Narrows Annual Loss in 2023

Fineline Cube Apr 26, 2024

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced its financial results for 2023, recording its...

Company

JW Therapeutics Reports 19.3% YOY Revenue Growth in 2023, Driven by CAR-T Therapy Carteyva

Fineline Cube Apr 26, 2024

China-based JW Therapeutics (HKG: 2126) has announced its financial results for 2023, with revenues reaching...

Company

MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact

Fineline Cube Apr 26, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first...

Company

Hua Medicine Reports 2023 Revenues of RMB 76.6 Million, Driven by Hypoglycemic Agent HuaTangNing

Fineline Cube Apr 26, 2024

China-based biopharmaceutical company Hua Medicine (HKG: 2552) has released its financial report for 2023, with...

Company Deals

Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round

Fineline Cube Apr 26, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai...

Company

Huadong Medicine’s Lidocaine-Containing Hyaluronic Acid Gel Accepted for NMPA Review

Fineline Cube Apr 26, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Policy / Regulatory

China’s NHC to Assume Management of Human Genetic Resources from May 2024

Fineline Cube Apr 26, 2024

The National Health Commission (NHC) of China has announced that the State Council has approved...

Company Drug

Chia Tai Tianqing’s TQA3038 siRNA Drug Completes Phase I Clinical Trial for Chronic Hepatitis B

Fineline Cube Apr 26, 2024

Chia Tai Tianqing has announced the successful completion of a Phase I clinical study for...

Company Drug

US FDA Greenlights Henlius Biotech’s Hanquyou as Biosimilar to Roche’s Herceptin

Fineline Cube Apr 26, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has achieved a significant milestone with the US Food...

Company

Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches

Fineline Cube Apr 26, 2024

France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter...

Company Drug

Novartis Receives Positive Interim Results for Antimalarial Coartem in Infants

Fineline Cube Apr 26, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced interim results from a Phase II/III clinical...

Company

Bristol Myers Squibb Reports 6% YOY Revenue Growth in Q1 2024, Driven by Eliquis and Reblozyl

Fineline Cube Apr 26, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has reported a 6% year-on-year (YOY) increase...

Posts pagination

1 … 354 355 356 … 651

Recent updates

  • Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication
  • Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal
  • Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate
  • Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer
  • Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication

Company Deals

Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal

Company Deals

Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate

Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.